Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| Great technology, great team, contributed to sales and the EBITDA margins |
| This was driven by strong performance in our medical interventional, industrial coatings and polymer processing product lines, which more than offset continued weakness in our electronics product lines |
| Throughout his career, Chris has demonstrated track record of operating performance improvement and shareholder value creation |
| At the outset, I'd like to recognize the dedicated Nordson team who leverage the NBS Next growth framework to deliver solid first quarter results |
| ATS ability to outperform their decremental targets in the quarter is a testament to this work |
| Through all of this, our ATS leaders have done a very good job of implementing the NBS Next growth framework and positioning themselves for future growth |
| This focus, in addition to simplifying and strategically adjusting costs, led to strong incremental margins, resulting in adjusted earnings per share of $2.21 |
| We remain very positive about the growth opportunities driving the next electronics cycle, including AI, automotive electronics, onshoring, CHIPS Act, and more |
| Our medical interventional solutions product lines continue to grow double-digits, buoyed by trends in non-invasive surgeries and the aging population |
| The ARAG integration is going well and the team contributed to our sales and EBITDA margin performance in the quarter |
| It is exciting to see NBS Next becoming a competitive advantage for Nordson and how the steady deployment across Nordson is positively impacting our financial results |
| We serve patient care, we serve surgical applications, and we see pretty good order entry there |
| We have some pretty good growth in surgical applications, and so that's where we're beginning to see some pretty good order entry and pretty good shipment |
| But the more interesting part is we have some pretty nice growth in patient care |
| As I mentioned at the beginning of the call, the decisions our teams are making to focus on top products serves our customers well, enhances our product mix and improves our gross margins |
| Clearly, we will have solid incrementals |
| During the quarter, we also had higher parts sales and improved factory efficiencies, which helped drive the year-over-year improvements |
| EBITDA, adjusted for acquisition related items in both periods, totaled $197 million or 31% of sales, a 9% increase over the prior year EBITDA of $181 million, driven by improved gross margins and cost controls as well as contribution from the ARAG acquisition |
| The team had a big win when one of our medical device customers placed a large order and the team was able to respond quickly, serving dynamic changes in demand and delighting this top customer |
| This improvement continues to demonstrate the benefits of our successful execution of the Ascend strategy |
| This has led to significant improvement in their on-time delivery performance over the last six months |
| Organic sales increased 2% over the prior year first quarter, continuing to build upon a record fiscal 2023 for this segment |
| Ascend has really been successful |
| A strong quarter |
| I mean, pretty remarkable growth |
| On slide 7, you'll see Medical and Fluid Solutions sales of $160 million increase 3% compared to the prior year's first quarter, driven by another quarter of double-digit growth in our medical interventional solutions product line, offsetting softness in our medical fluid components and fluid solutions product line |
| What we also see is that you have strong backlog in big system business like our industrial coatings product line and our polymer process product line |
| The 300 basis point improvement in EBITDA margin over the first quarter of 2023 is due primarily to a combination of factory efficiency gains and cost actions, coupled with leveraging the organic growth in medical interventional solutions |
| Operator Our strong operating performance reflects the strength of our diversified end markets, close to the customer model, differentiated precision technology products and rigorous implementation of NBS Next growth framework |
| And continued deployment of the Ascend strategy positions us well for long term growth |
| Statement |
|---|
| Second quarter guidance considers weaker electronics end markets and the impact of the Chinese New Year shutdown |
| What we will tell you is the demand or shipments for ATS in the quarter was as expected, weaker as we had expected |
| The decrease in sales was driven by weakness across the segment, primarily electronics dispense products serving semiconductor end markets |
| Our product lines exposed to the semiconductor electronics cycle experienced a weaker demand, as expected in the first quarter |
| During the quarter, we started to anniversary the weakness of last year's biopharma destocking, which was a significant headwind for this segment in fiscal 2023 |
| First quarter EBITDA was $22 million or 19% of sales, which trailed the prior year first quarter EBITDA of $31 million, excluding acquisition related costs |
| If you look at the second quarter guide there, right, what I would tell you is what, you're what you're not seeing, again, is the weakness in electronics end market that's also weighing down the second quarter as well in the ATS segment |
| Turning to slide 8, you'll see Advanced Technology Solutions sales were $119 million, an 18% decrease compared to the prior year first quarter |
| What you have in MFS is this medical fluid components which had the biopharma exposure, last year was a significant decline, right? And so, that significant decline essentially put MFS in a negative growth last year |
| And if you really think about that, right, the guidance that we gave for the second quarter here at the midpoint, we've got sales growth of 1%, which would imply negative organic growth of 4% |
| Saree Boroditsky I believe book-to-bill was below 1 again this quarter |
| Sundaram Nagarajan Europe is – the market is down |
| Consistent with prior quarters, the organic sales decrease was primarily volume, partially offset by price as we continue to pass through year-over-year cost inflation |
| We have now anniversaried the negative impact of biopharma destocking that was a headwind in fiscal 2023 |
| What we mean by that is we don't have any anxiety in the customer order patterns, right? So, if you go back even four quarters ago, you still had people – might be still concerned about supply chain constraints, and that doesn't exist anymore |
| If you think about that, that's about – half of that negative organic growth is coming from the Chinese New Year |
| Matt Summerville Just as a follow-up, and sticking with ATS, it sounded like in your prepared remarks that you saw maybe fairly broad weakness across the segment |
| Hopefully, I will answer the questions because I had little trouble hearing you completely |
| So, what you're really seeing is some strong comparisons that are difficult to keep up with |
| But the order entry has not picked up, as we had hoped |
Please consider a small donation if you think this website provides you with relevant information